Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
Portugal, Spain406 participantsStarted 2025-10-22
Plain-language summary
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global IBS symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks.
Secondary efficacy objectives are to evaluate the impact of Saccharomyces boulardii CNCM I-745 on quality of life of IBS patients and on global and individual IBS symptoms, using the IBS-SSS, in comparison to placebo at regular intervals over a 3-month treatment period. This research also aims to evaluate the proportion of patients who improved ≥ 50 points on IBS-SSS and the proportion of responders according to the European Medicines Agency (EMA) definition (based on the patient's global assessment of efficacy and on abdominal pain score), after 8 weeks of treatment. Secondary safety objective is to evaluate the safety profile and tolerability of Saccharomyces boulardii CNCM I-745 capsules 500 mg/day in IBS patients in comparison to placebo
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female aged ≥ 18 and ≤ 65 years.
✓. Diagnosis of IBS of any subtype, except constipation predominant (IBS-C), according to Rome IV criteria.
✓. IBS-SSS total score ≥ 175 at inclusion.
✓. Able and willing to maintain their nutrition habits throughout the study participation.
✓. Able to understand and willing to comply with study requirements and to provide written informed consent.
✓. For women of childbearing potential: willing to use one or more acceptable birth control method throughout the study participation.
Exclusion criteria
✕. Diagnosis of IBS-C according to Rome IV criteria.
✕. Patient with more than 5 bowel movements per day on average during the screening period, according to the patient's diary (BSFS).
✕. Severe illness(es) or medical condition(s), including gastrointestinal pathologies (other than IBS): gastrointestinal ulcers, coeliac disease, inflammatory bowel disease, bowel cancer, acute or chronic diarrhea secondary to confirmed infectious gastroenteritis, or enteral or parenteral nutrition.
What they're measuring
1
To demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global Irritable Bowel Syndrome (IBS) symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks.
✕. History of abdominal surgery (except for appendectomy, cholecystectomy, surgery for hemorrhoids or cesarian section, more than 6 months prior to inclusion).
✕. Familial colorectal cancer syndrome (Lynch, Familial Adenomatous Polyposis).
✕. Fecal transplant within 6 months prior to screening.
✕. Use of products marketed as prebiotics, probiotics or synbiotics within 2 weeks prior to screening. These products, with the exception of the investigational product, will not be allowed during the trial. Regular cheese or yogurt containing lactic acid bacteria are not an exclusion criterion.
✕. Systemic antibiotic or antimycotic treatment within 2 weeks prior to randomization. These treatments are not allowed during the study.